Sarepta's Former COO David Howton Sold $31.2M — Now Selling SLDB Stock at $6/Share

David T. Howton, former COO of Sarepta Therapeutics (SRPT), accumulated $31.2 million in career stock sales across 120 transactions. Now at Solid Biosciences (SLDB), his February 2026 filings show a starkly different scale: selling 45,240 shares of SLDB at just $5.82-$6.44/share for roughly $286K total.

The Numbers

Metric	Value
Career Sell Value	$31.2M
Career Buy Value	$0
Total Transactions	120
Last Transaction	2026-02-02
Shares Remaining	105,077

Recent Activity

Date	Type	Shares	Price	Est. Value
2026-02-18	Sell	7,469	$5.8233	$43K
2026-02-13	Exercise	14,687	N/A	$0
2026-02-13	Exercise	14,687	N/A	$0
2026-02-02	Sell	37,771	$6.4369	$243K
2026-01-31	Exercise	42,275	N/A	$0

Howton's transition from Sarepta to Solid Biosciences is visible in his Form 4 timeline. January-February 2026 filings show systematic SLDB option exercises (42K-79K shares) followed by sales at single-digit prices. The contrast with his Sarepta tenure — where individual transactions could reach millions — highlights the difference between a $10B+ rare disease leader and a $250M gene therapy company.

What It Means

Howton's career insider profile tells a story of two acts: $31.2M in Sarepta sales at premium biotech prices, followed by small-dollar SLDB selling at depressed valuations. The 105,077 shares remaining across his filings suggest he maintains meaningful exposure, but at ~$6/share that represents only ~$630K — a fraction of what a single Sarepta sale generated.

The Sarepta-to-Solid-Biosciences career path is common in biotech: executives move from established rare disease companies to earlier-stage gene therapy plays. For SRPT investors, Howton's departure and complete divestiture removes a long-tenured operator from the shareholder base. For SLDB watchers, a former Sarepta COO selling at $6 from a company developing DMD gene therapies adds an insider sentiment data point — though early-stage biotech selling is often driven by exercise deadlines rather than conviction.

What to Watch

• Whether Howton continues exercising and selling SLDB options in Q1 2026
• Solid Biosciences' DMD gene therapy clinical data readouts
• Sarepta's Elevidys commercial trajectory under new leadership
• Any additional career moves that generate new Form 4 filings